share_log

Citigroup | SC 13G: Statement of acquisition of beneficial ownership by individuals-Citigroup Global Markets Inc.(7.7%),Citigroup Financial Products Inc.(7.7%), etc.

Citigroup | SC 13G: Statement of acquisition of beneficial ownership by individuals-Citigroup Global Markets Inc.(7.7%),Citigroup Financial Products Inc.(7.7%), etc.

花旗集團 | SC 13G：超過5%持股股東披露文件-Citigroup Global Markets Inc.(7.7%),Citigroup Financial Products Inc.(7.7%)等
美股SEC公告 ·  2024/11/13 02:29

Moomoo AI 已提取核心訊息

Citigroup Inc. and its affiliates, including Citigroup Global Markets Inc., Citigroup Financial Products Inc., and Citigroup Global Markets Holdings Inc., have filed a Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a beneficial ownership of 1,000,036 shares of common stock in Eagle Pharmaceuticals, Inc. This represents 7.7% of the class, as of the event date of September 30, 2024. The filing, made under Rule 13d-1(b), signifies that the shares were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of the issuer. The principal business office for all reporting entities is located at 388 Greenwich Street, New York, NY 10013. Citigroup Inc. and its subsidiaries have affirmed that the information provided in the statement is true and correct to the best of their knowledge.
Citigroup Inc. and its affiliates, including Citigroup Global Markets Inc., Citigroup Financial Products Inc., and Citigroup Global Markets Holdings Inc., have filed a Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a beneficial ownership of 1,000,036 shares of common stock in Eagle Pharmaceuticals, Inc. This represents 7.7% of the class, as of the event date of September 30, 2024. The filing, made under Rule 13d-1(b), signifies that the shares were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of the issuer. The principal business office for all reporting entities is located at 388 Greenwich Street, New York, NY 10013. Citigroup Inc. and its subsidiaries have affirmed that the information provided in the statement is true and correct to the best of their knowledge.
花旗集團及其關聯公司，包括花旗全球貨幣市場股份有限公司，花旗金融產品股份有限公司和花旗全球貨幣市場控股公司，於2024年11月12日向證券交易委員會提交了13G表格，表明在Eagle Pharmaceuticals, Inc.擁有1,000,036股普通股的有益所有權。截至2024年9月30日的事件日期，這代表了該類股的7.7%。根據規則13d-1(b)提交的申報表明這些股份是在正常業務過程中獲取的，並非目的是改變或影響發行人的控制。所有報告實體的主要業務辦公地點位於紐約州紐約市格林威治大街388號。花旗集團及其子公司已確認聲明中提供的信息據其最佳知識屬實和正確。
花旗集團及其關聯公司，包括花旗全球貨幣市場股份有限公司，花旗金融產品股份有限公司和花旗全球貨幣市場控股公司，於2024年11月12日向證券交易委員會提交了13G表格，表明在Eagle Pharmaceuticals, Inc.擁有1,000,036股普通股的有益所有權。截至2024年9月30日的事件日期，這代表了該類股的7.7%。根據規則13d-1(b)提交的申報表明這些股份是在正常業務過程中獲取的，並非目的是改變或影響發行人的控制。所有報告實體的主要業務辦公地點位於紐約州紐約市格林威治大街388號。花旗集團及其子公司已確認聲明中提供的信息據其最佳知識屬實和正確。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間